 |
||
|---|---|---|
| 【ProductName】 |
DCAF15 Antibody Blocking Peptide |
|
| 【Cat NO.】 |
K111180P-Ag |
|
| 【Source】 |
Synthetic |
|
| 【Storage】 |
Store at -20℃，2 years.Avoid freeze/thaw cycles. |
|
| 【Appearance】 |
Lyophilized powder |
|
| 【Swiss Prot】 |
Q66K64 |
|
| 【Gene ID】 |
90379 |
|
| 【Application】 |
Blocking Peptide of K111180P Antibody |
|
| 【Purification】 |
HPLC |
|
| 【Activity】 |
Not tested |
|
| 【Note】 |
Please allow the product to equilibrate to room temperature in a dry environment before opening the packaging. |
|
|
||
Background：
Substrate-recognition component of the DCX(DCAF15) complex， a cullin-4-RING E3 ubiquitin-protein ligase complex that mediates ubiquitination and degradation of target proteins (PubMed:16949367， PubMed:31452512). The DCX(DCAF15) complex acts as a regulator of the natural killer (NK) cells effector functions， possibly by mediating ubiquitination and degradation of cohesin subunits SMC1A and SMC3 (PubMed:31452512). May play a role in the activation of antigen-presenting cells (APC) and their interaction with NK cells (PubMed:31452512).Binding of aryl sulfonamide anticancer drugs， such as indisulam (E7070) or E7820， change the substrate specificity of the DCX(DCAF15) complex， leading to promote ubiquitination and degradation of splicing factor RBM39 (PubMed:28437394， PubMed:28302793， PubMed:31693891， PubMed:31452512). RBM39 degradation results in splicing defects and death in cancer cell lines (PubMed:28437394， PubMed:28302793， PubMed:31693891). Aryl sulfonamide anticancer drugs change the s